DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
08 Março 2024 - 11:33AM
Montrouge, France, March 8, 2024
DBV Technologies announces filing of
2023 Annual Report on Form 10-K and Universal Registration
Document
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company focused on treatment options for food
allergies and other immunologic conditions with significant unmet
medical need (the “Company”), today announced the filing, for the
year ended December 31, 2023, of its Annual Report on Form 10-K
with the U.S. Securities and Exchange Commission (“SEC”) and its
Universal Registration Document (“URD”) with the French market
authority, “Autorité des Marchés Financiers” (“AMF”).
These documents can be accessed on the Investors
section of the Company's website at www.dbv-technologies.com. In
addition, the URD is available on the AMF’s website at
www.amf-france.org and the Form 10-K is available on the SEC’s
website at www.sec.gov.
Printed copies of both documents are available,
free of charge, at the Company’s headquarters and registered office
located at 177-181 avenue Pierre Brossolette 92120 Montrouge,
France.
About DBV Technologies DBV
Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
technology platform, Viaskin™, to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin platform is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Montrouge,
France, with North American operations in Basking Ridge, NJ. The
Company’s ordinary shares are traded on segment B of Euronext Paris
(Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one-half of one ordinary share) are traded on the
Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit
www.dbvtechnologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact Katie
MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAurora KrauseDBV
Technologiesaurora.krause-ext@dbv-technologies.com
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024